Applied Filters
Mylan’s NHK-Fintiv challenge denied by SCOTUS
The US Supreme Court has rejected a bid from generic drugmaker Mylan to overturn the NHK-Fintiv rule.
Groups urge Fed Circ to rehear Biogen patent case
Pharma, biotech and chemical industry groups have asked the US Court of Appeals for the Federal Circuit to review its decision to invalidate a Biogen patent for lacking written description.
Bristol Meyers can’t convince circuit to overturn $1.2bn ruling
The US Court of Appeals for the Federal Circuit has turned down a Bristol Myers Squibb subsidiary’s appeal to overturn a controversial $1.2 billion patent verdict loss against Kite Pharma.
Hikma ‘skinny’ label does not infringe Amarin patents
Hikma Pharmaceuticals has secured a win in its “skinny label” patent suit with Amarin Pharmaceuticals, following a ruling handed down by a federal court in the state of Delaware.
Apotex asks Supreme Court to overturn Teva ‘Bendeka’ ruling
Apotex has asked the US Supreme Court to reconsider a US Court of Appeals for the Federal Circuit ruling upholding four of Teva Pharmaceutical’s cancer drug patents.
BioDelivery Sciences ‘pleased’ with mixed ruling over Opioid drug claims
A Delaware Federal Court has upheld some of the validity of challenged claims in two patents related to BioDelivery Sciences’ opioid medication Belbuca, but invalidated others.
Gilead, BMS, Janssen facing HIV generic antitrust suit
Gilead, Bristol-Myers Squibb and Janssen are facing accusations that they suppressed competition in the market for drugs used to treat the human immunodeficiency virus.
Intubated patients sedative patent the focus of ACS Dobfar suit
Sun Pharmaceutical has been sued by ACS Dobfar subsidiary InfoRLife and WG Critical Care for allegedly infringing on a patent with its proposed midazolam-an anaesthesia medication.
Generics win anti-pay-for-delay bill challenge
The Association for Accessible Medicines, which represents manufacturers of generics and biosimilars, has succeeded in challenging a California bill that characterises “reverse payment” or “pay-for-delay” patent settlements as anticompetitive and unlawful.
Pharmavite accuses Bausch, GSK of ‘sham’ patent litigation
Nutritional supplements manufacturer Pharmavite has filed an antitrust suit against Bausch & Lomb and GlaxoSmithKline, claiming that they are filing sham patent litigation related to its “PreserVision” products.
